PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.34%
Positive EBIT growth while Biotechnology median is negative. Peter Lynch might see a strong competitive advantage in operations.
30.35%
Positive operating income growth while Biotechnology is negative. Peter Lynch would spot a big relative advantage here.
30.26%
Positive net income growth while Biotechnology median is negative. Peter Lynch would view this as a notable competitive advantage.
30.58%
EPS growth of 30.58% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
33.88%
Diluted EPS growth of 33.88% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
0.94%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
5.92%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
10.50%
OCF growth of 10.50% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
10.43%
FCF growth of 10.43% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10668.67%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
79.98%
OCF/share CAGR of 79.98% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
60.25%
3Y OCF/share growth of 60.25% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-3178.86%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
82.89%
Net income/share CAGR of 82.89% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
76.87%
3Y net income/share CAGR of 76.87% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
496.60%
Equity/share CAGR of 496.60% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
159.22%
5Y equity/share CAGR of 159.22% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
-89.45%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.48%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-43.72%
Negative BV/share change while Biotechnology median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
14.13%
Debt growth of 14.13% while Biotechnology median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
-30.15%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-30.87%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.